Joint inflammation pathophysiology

Synovitis

Joint inflammation (synovitis) in inflammatory arthritis follows a common core pathophysiological sequence - immune cell infiltration of the synovium, cytokine-driven synovial proliferation (pannus formation), and progressive cartilage/bone destruction - though the specific triggering immune mechanism varies by disease
Underlies the shared clinical presentation (joint swelling, pain, stiffness, warmth) across the inflammatory arthritides, despite their differing underlying causes (autoimmune in RA, crystal-mediated in gout, infectious in septic arthritis)

Immune cell infiltration (T cells, B cells, macrophages) into the normally thin synovium, driven by disease-specific triggers (autoantibodies and citrullinated protein recognition in RA, crystal phagocytosis activating the inflammasome in gout) -> pro-inflammatory cytokine release (TNF-alpha, IL-6, IL-1) -> synovial fibroblast/macrophage activation and proliferation -> in chronic inflammatory arthritis, formation of an invasive pannus (proliferative, locally destructive synovial tissue) that erodes adjacent cartilage and bone
Osteoclast activation (via the RANK/RANKL pathway, upregulated by inflammatory cytokines) drives the bony erosion characteristic of chronic inflammatory arthritis, distinguishing it radiologically from the subchondral sclerosis/osteophyte pattern of osteoarthritis

Clinical signs of synovitis (warmth, swelling, tenderness, reduced range of motion) reflect this underlying process; synovial fluid analysis (raised white cell count, neutrophil-predominant in acute inflammatory/infectious arthritis) provides direct evidence of the inflammatory process
Imaging (ultrasound, MRI) can detect synovitis and early erosive change before it is clinically or radiographically (X-ray) apparent, reflecting the same underlying pannus/cytokine-driven process at an earlier stage

This shared pathophysiological pathway is the rationale for targeted biologic therapy - TNF inhibitors, IL-6 receptor blockers, and IL-1 blockers each interrupt a specific step of this cytokine cascade, with drug choice informed by which disease and which cytokine pathway predominates
Early, effective suppression of this inflammatory cascade prevents the progression to irreversible pannus-mediated joint destruction - the physiological basis for "treat to target" early aggressive treatment strategies

Rheumatoid arthritis (the paradigm pannus-forming disease), psoriatic arthritis, gout (crystal-triggered inflammasome activation), septic arthritis (infection-triggered)

Understanding that bony erosion in inflammatory arthritis is actively driven by cytokine-stimulated osteoclast activity (not simply mechanical wear) explains why effective anti-cytokine therapy can halt erosion progression, and why early treatment before extensive pannus formation produces substantially better long-term joint outcomes than delayed treatment

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.